期刊文献+

脑星形细胞瘤组织中p16、bcl-2、bax蛋白的表达及其意义 被引量:4

Expression and Significance of p16 and bcl-2、bax Proteins in Astrocytomas
下载PDF
导出
摘要 目的 探讨p16、bcl 2、bax蛋白在脑星形细胞瘤中的表达及其意义。方法 采用S P免疫组织化学法 ,检测p16、bcl 2、bax蛋白在 60例不同病理分级脑星形细胞瘤组织中的表达情况。结果  60例脑星形细胞瘤组织中 ,p16、bcl 2、bax蛋白表达的阳性率分别为 5 0 .0 % ( 30 /60 )、5 8.3% ( 35 /60 )、66.7% ( 40 /60 ) ,其中 p16蛋白阳性表达与病理分级有显著性相关 (P <0 .0 5 ) ;bcl 2、bax蛋白表达与病理分级无相关性 (P >0 .0 5 )。 60例脑星形细胞瘤组织中 ,p16、bcl 2、bax蛋白共同表达率 :Ⅰ级为 47.8% ( 11/2 3) ,Ⅲ~Ⅳ级为 0 ( 0 /16) ;在bcl 2、bax蛋白表达的基础上 ,不同病理分级组织中 p16蛋白的缺失率 :Ⅰ级为 4.3% ( 1/2 3) ,Ⅲ~Ⅳ级为 5 0 .0 % ( 8/16) ,有非常显著性差异 (P <0 .0 1)。结论 p16蛋白表达与脑星形细胞瘤的发生发展密切相关 ;在脑星形细胞瘤的发展过程中 ,bcl 2、bax、p16蛋白可能有某种协调作用。 Objective To study the expression of p16?bcl 2 and bax proteins,as well as their significance in the development and malignant progression of astrocytomas.Methods The expression of p16 protein and bcl 2?bax proteins were studied by S P immunohistochemistry in 60 cases of astrocytomas.Results p16 protein depletion was in accordance with the increasing grade of astrocytoma malignancy( P <0.05).The expression of bcl 2 and bax showed no significant correlation with grades of astrocytomas( P > 0.05 ).The co expression rate of p16,bcl 2 and bax was 47.8%(11/23) in astrocytomas grade I,and 0(0/16) in grade Ⅲ and Ⅳ. On the basis of the expression of bcl 2 and bax, the deletion rate of p16 was 4.3%(1/23) in astrocytomas grade I,and 50.0%(8/16) in grade Ⅲ and Ⅳ.( P <0.01).Conclusion The expression of p16 protein is associated with progression of astrocytomas.p16 protein and bcl 2,bax protein play a role in the oncogenesis and progression of astrocytomas.
出处 《实用癌症杂志》 2002年第2期142-144,共3页 The Practical Journal of Cancer
关键词 脑肿瘤 星形细胞瘤 P16蛋白 BCL-2蛋白 BAX蛋白 免疫组织化学 Astrocytomas p16 protein bcl 2 protein bax protein Immunohistochemistry
  • 相关文献

参考文献4

二级参考文献7

共引文献7

同被引文献32

  • 1许春梅,董卫国,余保平,罗和生,于皆平.低氧诱导因子-1α及诱导型一氧化氮合酶在炎症性肠病中的表达[J].第四军医大学学报,2004,25(17):1558-1561. 被引量:4
  • 2许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1368
  • 3徐庆中 卢德宏.脑肿瘤病理分类和诊断工作中的新问题[J].中华病理学杂志,1995,24(5):327-327.
  • 4[1]Neufeld G, Cohen T, Stela G, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J, 1999, 13:9- 22
  • 5[3]Friedrichs K, Gluba S, Eidtmann H, et al. Overexpression of p53 and prognosis in breast cancer[J]. Cancer, 1993,72(12):3641
  • 6[4]Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor [J]. J Biol Chem, 1991, 266 (18): 11947- 11954
  • 7[5]Brock TA, Dvorak HF, Senger DR. Tumor- secreted vascular permeability factor increase cytosolic Ca2+ and von Willebrand factor release in human endothelial cells [J]. Am J Pathol, 1991, 138(1): 213- 221
  • 8[6]Folkman J. What is the evidence that tumors are angiogenesis de-pendent [J]? J Natl Cancer Inst, 1990, 82(1): 4- 6
  • 9Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase Ⅱ in nomal and neoplastic human tissues[J]. Cancer, 1997, 75(9):1340-1346.
  • 10Nishikawa R, Fumari F B, Hin L, et al. Loss of p16 expression is frequent in high grade gliomas[J].Cancer Res, 1995, 55(9):1941-1945.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部